Lyell Immunopharma
LYEL
118 hedge funds and large institutions have $256M invested in Lyell Immunopharma in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
42% more capital invested
Capital invested by funds: $180M → $256M (+$76.2M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more funds holding
Funds holding: 106 → 118 (+12)
10% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 30
0.18% more ownership
Funds ownership: 2.44% → 2.62% (+0.18%)
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.92M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.68M |
| 3 |
BlackRock
New York
|
+$1.59M |
| 4 |
Morgan Stanley
New York
|
+$1.51M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$1.34M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GS
126
GTS Securities
New York
| – | -$22.2K | -755 | Closed |
|
127
Allspring Global Investments
Charlotte,
North Carolina
| – | -$18.2K | -620 | Closed |
|
128
US Bancorp
Minneapolis,
Minnesota
| – | -$3.47K | -118 | Closed |
|
129
Simplex Trading
Chicago,
Illinois
| – | -$1.01K | -28 | Closed |
|
|
CAL
130
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$288 | +8 | New |
|
LYEL Hedge Fund Activity: Q4 2023 in Review
118 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2023, worth a combined $256M — up 42% from $180M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LYEL positions and 13 closed out — a net gain of 12 holders — while 33 added to existing stakes and 30 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.92M. The largest seller was Vanguard Group, cutting an estimated $5.95M.
- 118 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2023, up from 106 in Q3 2023.
- Funds reported $256M of Lyell Immunopharma stock for Q4 2023, up 42% quarter-over-quarter.
- 25 funds opened new Lyell Immunopharma positions in Q4 2023 and 13 closed out, a net change of +12 holders.
- The largest Lyell Immunopharma buyer in Q4 2023 was Citadel Advisors, an estimated $4.92M added.
- The largest Lyell Immunopharma seller in Q4 2023 was Vanguard Group, an estimated $5.95M sold.
Based on aggregated 13F filings for Q4 2023.